Annual Report 2019.pdf - Medivir

30+ "Hacksell" profiles LinkedIn

ACADIA Pharmaceuticals Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of small molecule darugs for the treatment of central nervous system disorders. For further information please contact: Uli Hacksell, Ph.D., Chief Executive Officer, or Thomas H. Aasen, Vice President and Chief Financial Officer, both of ACADIA Pharmaceuticals Inc., +1-858-558 Uli Hacksell CERC stock SEC Form 4 insiders trading. Uli has made over 22 trades of the Cerecor Inc stock since 2012, according to the Form 4 filled with the SEC. Most recently Uli bought 20,000 units of CERC stock worth $15,000 on 10 December 2016. 2021-04-07 · Uli Hacksell Hacksell, född 1950, har under 30 år arbetat inom farmaceutisk industri och bioteknikbolag. Som vd för San Diego-baserade ACADIA Pharmaceuticals (2000-2015) ledde han utvecklingen från privat start-up företag till publikt mångmiljardbolag och framtagandet av det första och enda godkända läkemedlet mot psykos hos Parkinsonpatienter. Dr. Uli Hacksell är sedan 3 maj 2018 styrelseledamot i Medivir och har en bakgrund från över 25 år i ledande befattningar på stora läkemedels- och bioteknikföretag och över 10 års erfarenhet som vd för publika bolag. Som vd för ACADIA Pharmaceuticals 2000–2015 ledde Uli Hacksell utvecklingen från privat start-up företag till ACADIA Pharmaceuticals Inc. 2010 EQUITY INCENTIVE PLAN.

Uli hacksell acadia pharmaceuticals

Titel: Ledamot sedan 2018. Utbildning: Apotekare och Farm dr. Bakgrund: Över 25 år i ledande befattningar på stora läkemedels- och bioteknikföretag och över 10 års erfarenhet som vd för publika bolag. Som vd för ACADIA Pharmaceuticals 2000-2015 ledde Hacksell utvecklingen från privat start-up företag till publikt mångmiljardbolag.

nyheter från nyhetsbyrån direkt - Nyhetsbyrån Direkt - Aktiellt

Att stämman beslutar om val av Uli Hacksell till styrelsens ordförande. Som vd för San Diego-baserade ACADIA Pharmaceuticals Acadia Pharmaceuticals. Uli Hacksell har styrelseuppdrag i Medivir, Index Pharmaceuticals Holding, Active Biotech och Synact Pharma. SciLifeLab workshops: Drug Discovery – How are drugs born?

Beactica avancerar onkologiprojekt Beactica avancerar

Utbildning: Apotekare och Farm dr. Bakgrund: Över 25 år i ledande befattningar på stora läkemedels- och bioteknikföretag och över 10 års erfarenhet som vd för publika bolag. Som vd för ACADIA Pharmaceuticals 2000-2015 ledde Hacksell utvecklingen från privat start-up företag till publikt mångmiljardbolag. 2021-04-07 AcAdiA PhArmAceuticAls | 2013 AnnuAl rePort 1 Uli Hacksell, Ph.D. Chief Executive Officer Q. For ACADIA, 2013 was a transformational year.

9 Jul 2015 He was the CEO of ACADIA Pharmaceuticals from September 2000 to March 2015, and led the company from a private start-up to becoming a Acadia Pharmaceuticals CEO Uli Hacksell speaks at the Jefferies 2013 Global Healthcare Conference in New York, June 5, 2013. chief has "stepped down" as 29 Jun 2018 to March 2015, Dr. Hacksell served as the Chief Executive Officer and as a director of ACADIA Pharmaceuticals. Inc. From February 1999 to 11 Mar 2015 Hacksell was the long-time CEO of Acadia Pharmaceuticals who left the In another statement Wednesday, Acadia said Uli Hacksell retired 11 Mar 2015 Acadia Pharmaceuticals Inc. won't be seeking regulatory approval for nervous system disorders, said longtime Chief Executive Uli Hacksell 11 Mar 2015 San Diego biotech to submit Parkinson's drug application in second half of In another statement Wednesday, Acadia said Uli Hacksell retired ACADIA Pharmaceuticals (NASDAQ:ACAD) Insider Buying and Selling Activity 1/14/2015, Uli Hacksell, CEO, Sell, 30,000, $33.98, $1,019,400.00. 12/15/2014 2 Sep 2014 ACADIA Pharmaceuticals Inc. (ACAD), a biopharmaceutical company focused on said Uli Hacksell, Ph.D., Chief Executive Officer of ACADIA. ACADIA Pharmaceuticals, Inc. 3611 Valley Centre Drive. Suite 300 Uli Hacksell. CEO. Dr. Hacksell has 2834 - Pharmaceutical preparations.
Del gr

Uli has 1 job listed on their profile. See the complete profile on LinkedIn and discover Uli’s connections SAN DIEGO--(BUSINESS WIRE)--Mar. 11, 2015-- ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in neurological and related central nervous system disorders, today announced that Uli Hacksell, Ph.D., has retired as ACADIA’s Chief Executive Officer and as a member of Dr Uli Hacksell (1950) has over 20 years of international management experience from both large pharmaceutical and biotech companies. He has served as CEO at two NASDAQ-listed biopharmaceutical companies, Cerecor (2016–2017) and ACADIA Pharmaceuticals (2000–2015), and led ACADIA from a private start-up to becoming a public multibillion dollar company. ACADIA Pharmaceuticals Announces Retirement of Uli Hacksell, Ph.D., Chief Executive Officer Steve Davis Appointed Interim Chief Executive Officer March 11, 2015 04:02 PM Eastern Daylight Time 2021-04-07 · Uli Hacksells CV inkluderar 30 års arbete inom farmaceutisk industri och bioteknikbolag, däribland som vd för San Diego-baserade Acadia Pharmaceuticals. Uli Hacksell har styrelseuppdrag i Medivir, Index Pharmaceuticals Holding, Active Biotech och Synact Pharma. Uli Hacksell is considered to be independent in relation to the company as well as its senior management and in relation to major shareholders.

President and Chief Executive Officer . ACADIA Pharmaceuticals Inc. 3911 Sorrento Valley Boulevard . San Diego, CA 92121 (Name and Address of Agent for Service) (858) 558-2871 Uli Hacksell is Former President/CEO at Medivir AB. See Uli Hacksell's compensation, career history, education, & memberships. ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Q3 2014 Earnings Conference Call November 10, 2014 5:00 PM ET Executives Lisa Barthelemy – Director, Investor Relations Uli Hacksell – Chief Uli Hacksell. Born: 1950 Title: Member of the Board since 2018.. Education: PhD at Uppsala University.
Toysrus sea monkeys

Som vd för San Diego-baserade ACADIA Pharmaceuticals (2000-2015) ledde han utvecklingen från privat start-up företag till publikt mångmiljardbolag och framtagandet av det första och enda godkända läkemedlet mot psykos hos Parkinsonpatienter. ACADIA Pharmaceuticals Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of small molecule darugs for the treatment of central nervous system disorders. For further information please contact: Uli Hacksell, Ph.D., Chief Executive Officer, or Thomas H. Aasen, Vice President and Chief Financial Officer, both of ACADIA Pharmaceuticals Inc., +1-858-558 Uli Hacksell CERC stock SEC Form 4 insiders trading. Uli has made over 22 trades of the Cerecor Inc stock since 2012, according to the Form 4 filled with the SEC. Most recently Uli bought 20,000 units of CERC stock worth $15,000 on 10 December 2016.

They are Aerie Pharmaceuticals (Nasdaq: AERI), Acadia Pharmaceuticals that was profiled was Acadia Pharmaceuticals, and CEO Uli Hacksell gave a bold Aktieägare i SynAct Pharma föreslår Uli Hacksell som ny ledande positioner vid USA-baserade ACADIA Pharmaceuticals och Cerecor, samt. Uli Hacksell, born 1950, is a trained pharmacist and holds a PhD at US-based ACADIA Pharmaceuticals and Cerecor, as well as his time at Shareholders of SynAct Pharma proposes Uli Hacksell as new board member US-based ACADIA Pharmaceuticals and Cerecor, as well as his time at Astra. Shareholders of SynAct Pharma proposes Uli Hacksell as new board at US-based ACADIA Pharmaceuticals and Cerecor, as well as his time Uli Hacksell, som i dag ingår i Medivirs styrelse, ersätter bolagets Som vd för ACADIA Pharmaceuticals 2000–2015 ledde Uli Hacksell Uli Hacksells CV inkluderar 30 års arbete inom farmaceutisk industri och däribland som vd för San Diego-baserade Acadia Pharmaceuticals.
Adressändring dödsbo postnord

Active Biotech » Styrelse

Dr. Uli Hacksell är sedan 3 maj 2018 styrelseledamot i Medivir och har en bakgrund från över 25 år i ledande befattningar på stora läkemedels- och bioteknikföretag och över 10 års erfarenhet som vd för publika bolag. Som vd för ACADIA Pharmaceuticals 2000–2015 ledde Uli Hacksell utvecklingen från privat start-up företag till ACADIA Pharmaceuticals Inc. 2010 EQUITY INCENTIVE PLAN. 2004 EMPLOYEE STOCK PURCHASE PLAN (Full Titles of the Plans) Uli Hacksell, Ph.D.